Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Osterhaus, Jane T ^a   Purcaru, Oana ^b  

^a Wasatch Health Outcomes   (United States)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT;

ABSENTEEISM; ADULT; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ANKYLOSING SPONDYLITIS QUALITY OF LIFE SCALE; ARTICLE; AXIAL SPONDYLARTHRITIS; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CONTROLLED STUDY; DISCRIMINANT VALIDITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EMPLOYMENT STATUS; FEMALE; HEALTH SURVEY; HOME; HOUSEHOLD; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NONRADIOGRAPHIC AXIAL SPONDYLARTHRITIS; PRODUCTIVITY; PSYCHOMETRY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELIABILITY; SHORT FORM 36; SPONDYLARTHRITIS; TREATMENT RESPONSE; WORK PRODUCTIVITY SURVEY; WORKPLACE; MIDDLE AGED; PSYCHOLOGY; QUALITY OF LIFE; REPRODUCIBILITY; SPONDYLITIS, ANKYLOSING;

ADULT; CERTOLIZUMAB PEGOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; WORKPLACE;

EID: 84908140269     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4680     Document Type: Article

References (39)

1. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J: The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009, 60:717-727.
2. van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
3. Gran JT, Husby G, Hordvik M: Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 1985, 44:359-367.
4. Braun J, Baraliakos X, Godolias G, Böhm H: Therapy of ankylosing spondylitis-a review. Part I: Conventional medical treatment and surgical therapy. Scand J Rheumatol 2005, 34:97-108.
5. Reveille JD, Witter JP, Weisman MH: Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res 2012, 64:905-910.
6. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J: Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003, 23:61-66.
7. Dagfinrud H, Vollestad NK, Loge JH, Kvien TK, Mengshoel AM: Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 2005, 53:5-11.
8. Haywood KL, Garratt AM, Dziedzic K, Dawes PT: Patient centered assessment of ankylosing spondylitis-specific health related quality of life: evaluation of the Patient Generated Index. J Rheumatol 2003, 30:764-773.
9. Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL: Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009, 27:S118-S123.
10. Boonen A, Brinkhuizen T, Landewé R, van der Heijde D, Severens JL: Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 2010, 69:1123-1128.
11. Boonen A, de Vet H, van der Heijde D, van der Linden S: Work status and its determinants among patients with ankylosing spondylitis: a systematic literature review. J Rheumatol 2001, 28:1056-1062.
12. Kavanaugh A: Health economics: implications for novel antirheumatic therapies. Ann Rheum Dis 2005, 64:iv65-iv69.
13. Escorpizo R, Bombardier C, Boonen A, Hazes JM, Lacaille D, Strand V, Beaton D: Worker productivity outcome measures in arthritis. J Rheumatol 2007, 34:1372-1380.
14. Prasad M, Wahlqvist P, Shikiar R, Shih YC: A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics 2004, 22:225-244.
15. Mattke S, Balakrishnan A, Bergamo G, Newberry SJ: A review of methods to measure health-related productivity loss. Am J Manag Care 2007, 13:211-217.
16. Lofland JH, Pizzi L, Frick KD: A review of health-related workplace productivity loss instruments. Pharmacoeconomics 2004, 22:165-184.
17. Osterhaus JT, Purcaru O, Richard L: Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res Ther 2009, 11:R73.
18. Osterhaus JT, Purcaru O: Validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing work productivity within and outside the home in patients with psoriatic arthritis. Value Health 2013, 16:A601.
19. Osterhaus JT, Purcaru O: Discriminant validity, responsiveness and realiability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritis. Arthritis Res Ther 2014, 16:R140.
20. Beaton D, Bombardier C, Escorpizo R, Zhang W, Lacaille D, Boonen A, Osborne RH, Anis AH, Strand CV, Tugwell PS: Measuring worker productivity: frameworks and measures. J Rheumatol 2009, 36:2100-2109.
21. Landewé RBM, Rudwaleit M, van der Heijde D, Dougados M, Maksymowych WP, Braun J, Deodhar AA, Stach C, Hoepken B, Coteur G, Kielar D, Fichtner A, Arledge T, Sieper J: Effect of certolizumab pegol on signs and symptoms of ankylosing spondyltitis and non-radiographic axial spondyloarthritis: 24 week results of a double blind randomized placebo-controlled phase 3 axial spondyloarthritis study [Abstract 777]. Arthritis Rheum 2012, 64:S336-S337.
22. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams HJ, Wolfe F: Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993, 36:729-740.
23. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F: The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992, 35:498-502.
24. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R: ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:1811-1818.
25. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
26. Pavy S, Brophy S, Calin A: Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol 2005, 32:80-85.
27. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, McKenna SP, Tennant A, van der Heijde D, Chamberlain MA: Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003, 62:20-26.
28. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
29. Anderson JJ, Baron G, Van Der Heijde D, Felson DT, Dougados M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44:1876-1886.
30. Barber JA, Thompson SG: Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000, 19:3219-3236.
31. Cohen MR, Reda DJ, Clegg DO, Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies: Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. J Rheumatol 1999, 26:1752-1756.
32. Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, van Vollenhoven RF: Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Care Res 2009, 61:1592-1600.
33. Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P: Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology 2010, 49:1900-1910.
34. Kirwan J, Heiberg T, Hewlett S, Hughes R, Kvien T, Ahlmen M, Boers M, Minnock P, Saag K, Shea B, Suarez Almazor M, Taal E: Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol 2003, 30:868-872.
35. Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, Kvien TK, Minnock P, Newman SP, Quest EM, Taal E, Wale J: Incorporating the patient perspective into outcome assessment in rheumatoid arthritis-progress at OMERACT 7. J Rheumatol 2005, 32:2250-2256.
36. Maksymowych WP, Gladman D, Rahman P, Boonen A, Bykerk V, Choquette D, Dimond S, Fortin P, Karsh J, Klinkhoff AV, Mosher D, Mulholland K, Olszynski WP, Russell AS, Savage L, Shanner L, Shojania K, Starr M, Thomson G, Zummer M, Inman R, Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada: The Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. J Rheumatol 2007, 34:2273-2284.
37. Tang K, Escorpizo R, Beaton DE, Bombardier C, Lacaille D, Zhang W, Anis AH, Boonen A, Verstappen SM, Buchbinder R, Osborne RH, Fautrel B, Gignac MA, Tugwell PS: Measuring the impact of arthritis on worker productivity: perspectives, methodologic issues, and contextual factors. J Rheumatol 2011, 38:1776-1790.
38. Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D: Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology (Oxford) 2010, 49:812-819.
39. Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M, Emery P, van der Horst-Bruinsma IE, Inman R, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Sturrock R, de Vlam K, Sieper J: The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009, 68:770-776. A published erratum appears in Ann Rheum Dis 2011, 70:1519.